Pharmaceuticals Report Revolutionary Findings, Approved Treatments, Investor Conferences - Research Report on Celgene, Amgen, Biogen Idec, Regeneron, and Questcor

NEW YORK, September 3, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Celgene Corporation (NASDAQ: CELG), Amgen Inc. (NYSE: AMGN), Biogen Idec Inc. (NASDAQ: BIIB), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), and Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Celgene Corporation Research Report

On August 28, 2013, Celgene Corporation (Celgene) reported that it will participate at two investor conferences in September 2013, where the Company's management will give participants an overview of Celgene. According to Celgene, of the two conferences, the Morgan Stanley Healthcare Conference will be held on Tuesday, September 10, 2013 at 4:40 p.m. ET. Meanwhile, the Stifel Healthcare Conference is likely to take place on Wednesday, September 11, 2013, at 4:25 p.m. ET. Celgene informed that interested parties can view a live webcast via the Investor Relations section of the Company's website. The Full Research Report on Celgene Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-08-29/CELG ]

--

Amgen Inc. Research Report

On August 27, 2013, Amgen Inc. (Amgen) reported that it will report new information about omecamtiv mecarbil - a small molecule cardiac myosin activator that is being studied for the treating heart failure in collaboration with Cytokinetics. The Company also informed that it will also present data related to AMG 145- an investigational human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol (LDL-C), or "bad" cholesterol, from the blood. The Company stated that it will present the aforesaid updates at the upcoming ESC Congress 2013, organized by the European Society of Cardiology, in Amsterdam. On the other hand, the Company intends to release data from the phase 2b ATOMIC-AHF (Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure) study, during a Hot Line Late Breaking Trials Session on September 3 at 11:00 a.m. CEST. Sean E. Harper, M.D., Executive Vice President of Research and Development at Amgen, commented, "The data presented at this year's ESC Congress 2013 will highlight what we are doing through our R&D efforts to develop novel treatments that we hope will meet today's urgent cardiovascular needs." The Full Research Report on Amgen Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-08-29/AMGN ]

--

Biogen Idec Inc. Research Report

On August 29, 2013, Biogen Idec Inc. (Biogen Idec) reported that it will participate at the Morgan Stanley Global Healthcare Conference on Monday, September 9, 2013 at 3:15 p.m. ET, and a live webcast of the event will be available through Biogen Idec's Investors section at the Company website. The Company informed that it will also host archived recorded version of the webcast for 14 days after the presentation. The Full Research Report on Biogen Idec Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-08-29/BIIB ]

--

Regeneron Pharmaceuticals, Inc. Research Report

On August 29, 2013, Regeneron Pharmaceuticals, Inc. (Regeneron) reported that its EYLEA® (aflibercept) Injection received approval from the European Commission, for treating visual impairment due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO). George D. Yancopoulos, M.D., Ph. D., Chief Scientific Officer of Regeneron and President of Regeneron Laboratories, commented, "We are pleased with the approval of EYLEA in the E.U. in a second indication. Our Phase 3 studies showed that EYLEA improved visual outcomes significantly in Macular Edema following CRVO. This additional approval of EYLEA is great news for patients in Europe suffering from Macular Edema following CRVO, a debilitating disease affecting central vision." The Company also informed that EYLEA was approved in the United States for treating neovascular (wet) Age-related Macular Degeneration (AMD) in November 2011 and for Macular Edema following CRVO in September 2012. Regeneron further added that, EYLEA has also received approval in Europe, Japan, Australia, and in several other countries for use in wet AMD and in selected countries in South America for Macular Edema following CRVO. The Full Research Report on Regeneron Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-08-29/REGN ]

--

Questcor Pharmaceuticals, Inc. Research Report

On August 27, 2013, Questcor Pharmaceuticals, Inc. (Questcor) reported that its executive management will participate at the Morgan Stanley Global Healthcare Conference, to be held in New York City on September 10, 2013 at 4:40 p.m. ET (1:40 p.m. PT). The Company informed that live webcast of the presentation will be available on the Company website and a replay of the same can be accessed from Questcor website for an estimated 90 days post the event. The Full Research Report on Questcor Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.InvestorsReports.com/report/2013-08-29/QCOR ]

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

InvestorsReports.com

SOURCE Investors' Reports